Replimune Group, Inc. (REPL): Total Assets
$332.39M
As of 2026-03-31
$252.45M
As of 2026-06-30
-19.9%
3-year compound annual growth
-9.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $332.39M | -39.7% | 2026-06-29, Balance as of period end |
| 2025-03-31 | $551.33M | +13.0% | 2026-06-29, Balance as of period end |
| 2024-03-31 | $487.72M | -24.6% | 2025-05-22, Balance as of period end |
| 2023-03-31 | $646.59M | +40.2% | 2024-05-16, Balance as of period end |
| 2022-03-31 | $461.19M | -15.1% | 2023-05-18, Balance as of period end |
| 2021-03-31 | $543.10M | +132.0% | 2022-05-19, Balance as of period end |
| 2020-03-31 | $234.10M | +51.7% | 2021-05-20, Balance as of period end |
| 2019-03-31 | $154.33M | +136.9% | 2020-06-03, Balance as of period end |
| 2018-03-31 | $65.15M | n/a | 2019-06-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Replimune Group, Inc. (REPL) | 2026-03-31 | $332.39M | -39.7% |
| Prokidney Corp. (PROK) | 2025-12-31 | $335.57M | -23.9% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $343.32M | +114.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $351.53M | +4.8% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $305.88M | +42.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗